Losartan Slows Pancreatic Tumor Progression and Extends Survival of SPARC-Null Mice by Abrogating Aberrant TGFβ Activation

被引:67
作者
Arnold, Shanna A. [1 ,2 ]
Rivera, Lee B. [1 ,2 ]
Carbon, Juliet G. [1 ,2 ]
Toombs, Jason E. [1 ,2 ]
Chang, Chi-Lun [1 ,2 ]
Bradshaw, Amy D. [3 ]
Brekken, Rolf A. [1 ,2 ]
机构
[1] Univ Texas SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dept Surg, Div Surg Oncol, Dallas, TX 75390 USA
[2] Univ Texas SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dept Pharmacol, Dallas, TX 75390 USA
[3] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA
来源
PLOS ONE | 2012年 / 7卷 / 02期
基金
美国国家卫生研究院;
关键词
GROWTH-FACTOR-BETA; REGULATORY T-CELLS; RECEPTOR-TYPE-I; AORTIC-ANEURYSM; MARFAN-SYNDROME; MESENCHYMAL TRANSITION; ENDOTHELIAL-CELLS; MESANGIAL CELLS; MURINE MODEL; MOUSE MODEL;
D O I
10.1371/journal.pone.0031384
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Pancreatic adenocarcinoma, a desmoplastic disease, is the fourth leading cause of cancer-related death in the Western world due, in large part, to locally invasive primary tumor growth and ensuing metastasis. SPARC is a matricellular protein that governs extracellular matrix (ECM) deposition and maturation during tissue remodeling, particularly, during wound healing and tumorigenesis. In the present study, we sought to determine the mechanism by which lack of host SPARC alters the tumor microenvironment and enhances invasion and metastasis of an orthotopic model of pancreatic cancer. We identified that levels of active TGF beta 1 were increased significantly in tumors grown in SPARC-null mice. TGF beta 1 contributes to many aspects of tumor development including metastasis, endothelial cell permeability, inflammation and fibrosis, all of which are altered in the absence of stromal-derived SPARC. Given these results, we performed a survival study to assess the contribution of increased TGF beta 1 activity to tumor progression in SPARC-null mice using losartan, an angiotensin II type 1 receptor antagonist that diminishes TGF beta 1 expression and activation in vivo. Tumors grown in SPARC-null mice progressed more quickly than those grown in wild-type littermates leading to a significant reduction in median survival. However, median survival of SPARC-null animals treated with losartan was extended to that of losartan-treated wild-type controls. In addition, losartan abrogated TGF beta induced gene expression, reduced local invasion and metastasis, decreased vascular permeability and altered the immune profile of tumors grown in SPARC-null mice. These data support the concept that aberrant TGF beta 1-activation in the absence of host SPARC contributes significantly to tumor progression and suggests that SPARC, by controlling ECM deposition and maturation, can regulate TGFb availability and activation.
引用
收藏
页数:18
相关论文
共 64 条
  • [1] Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-β levels
    Agarwal, R
    Siva, S
    Dunn, SR
    Sharma, K
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 39 (03) : 486 - 492
  • [2] Losartan inhibits LPS-induced inflammatory signaling through a PPARγ-dependent mechanism in human THP-1 macrophages
    An, Jianbo
    Nakajima, Toshiaki
    Kuba, Keiji
    Kimura, Akinori
    [J]. HYPERTENSION RESEARCH, 2010, 33 (08) : 831 - 835
  • [3] Forced expression of MMP9 rescues the, loss of angiogenesis and abrogates metastasis of pancreatic tumors triggered by the absence of host SPARC
    Arnold, Shanna
    Mira, Emilia
    Muneer, Sabeeha
    Korpanty, Grzegorz
    Beck, Adam W.
    Holloway, Shane E.
    Manes, Santos
    Brekken, Rolf A.
    [J]. EXPERIMENTAL BIOLOGY AND MEDICINE, 2008, 233 (07) : 860 - 873
  • [4] Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma
    Arnold, Shanna A.
    Rivera, Lee B.
    Miller, Andrew F.
    Carbon, Juliet G.
    Dineen, Sean P.
    Xie, Yang
    Castrillon, Diego H.
    Sage, E. Helene
    Puolakkainen, Pauli
    Bradshaw, Amy D.
    Brekken, Rolf A.
    [J]. DISEASE MODELS & MECHANISMS, 2010, 3 (1-2) : 57 - 72
  • [5] Regulatory T Cells: Major Players in the Tumor Microenvironment
    Beyer, Marc
    Schultze, Joachim L.
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2009, 15 (16) : 1879 - 1892
  • [6] Cell-matrix interactions: The view from the outside
    Bornstein, P
    [J]. METHODS IN CELL-MATRIX ADHESION, 2002, 69 : 7 - 11
  • [7] SPARC-null mice display abnormalities in the dermis characterized by decreased collagen fibril diameter and reduced tensile strength
    Bradshaw, AD
    Puolakkainen, P
    Dasgupta, J
    Davidson, JM
    Wight, TN
    Sage, EH
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2003, 120 (06) : 949 - 955
  • [8] Enhanced growth of tumors in SPARC null mice is associated with changes the ECM
    Brekken, RA
    Puolakkainen, P
    Graves, DC
    Workman, G
    Lubkin, SR
    Sage, EH
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (04) : 487 - 495
  • [9] Angiotensin II blockade and aortic-root dilation in Marfan's syndrome
    Brooke, Benjamin S.
    Habashi, Jennifer P.
    Judge, Daniel P.
    Patel, Nishant
    Loeys, Bart
    Dietz, Harry C., III
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (26) : 2787 - 2795
  • [10] Bruns Christiane J., 1999, Neoplasia (New York), V1, P50, DOI 10.1038/sj.neo.7900005